Skip to the page

Data / New clinical trials / Company sponsors / PersonGen BioTherapeutics (Suzhou) Co., Ltd.

PersonGen BioTherapeutics (Suzhou) Co. trials: 43 (2026)

Source: ClinicalTrials.gov API v2 (U.S. National Library of Medicine).

ClinicalTrials.gov lists 43 trials with PersonGen BioTherapeutics (Suzhou) Co., Ltd. as lead sponsor, 12 of them recruiting or not yet recruiting.

The full list. Clinical trials led by PersonGen BioTherapeutics (Suzhou) Co., Ltd.: 43 rows for $5, every trial on ClinicalTrials.gov.

$10 of credit on sign-up, no card. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

For agents and scripts: this list is ordered at https://specstream.ai/data/clinical-trials/company/persongen-biotherapeutics-suzhou-co-ltd, and every list with its row count and price is at https://specstream.ai/data/lists.json.

The request: Every clinical trial PersonGen BioTherapeutics (Suzhou) Co., Ltd. leads on ClinicalTrials.gov, with phase, status, conditions and sites, and each new one.

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

Trials
43
Recruiting or not yet
12
Read on
November 19, 2026

Trials

The 25 newest of 43, each linked to its ClinicalTrials.gov record. The full list holds every one.

First postedNCT IDTitleSponsorPhaseStatusConditionsEnrollmentSource
June 3, 2026NCT07623681Single-arm, Open-label, Dose-escalating Phase I Clinical Study of PA3-17 Injection in Children and Adolescents With Relapsed/Refractory...PersonGen BioTherapeutics (Suzhou) Co., Ltd.Phase 1Not yet recruitingCD7+ T-ALL/LBL12clinicaltrials.gov
January 14, 2026NCT07338604Clinical Study of UTAA07 Injection in the Treatment of Hematologic and Lymphatic Systemic MalignanciesPersonGen BioTherapeutics (Suzhou) Co., Ltd.Early phase 1RecruitingHematolymphoid Malignancies15clinicaltrials.gov
December 31, 2025NCT07312630Clinical Study of LV009 Injection for the Treatment of Relapsed/Refractory CD19-Positive Hematologic and Lymphoid MalignanciesPersonGen BioTherapeutics (Suzhou) Co., Ltd.Early phase 1RecruitingNon-Hodgkin Lymphoma (NHL), Acute Lymphoblastic Leukemia (ALL), Adult19clinicaltrials.gov
December 16, 2025NCT07284927Clinical Study of LV009 Injection for the Treatment of Hematologic and Lymphoid MalignanciesPersonGen BioTherapeutics (Suzhou) Co., Ltd.Phase 1RecruitingNon-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia10clinicaltrials.gov
September 23, 2025NCT07188610PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/LymphomaPersonGen BioTherapeutics (Suzhou) Co., Ltd.Phase 2RecruitingCD7-positive Relapsed/Refractory T Lymphoblastic Leukemia/Lymphoma100clinicaltrials.gov
May 21, 2025NCT06982547Clinical Study on the Treatment of Refractory Rheumatoid Arthritis With UTAA91 InjectionPersonGen BioTherapeutics (Suzhou) Co., Ltd.Early phase 1Not yet recruitingRheumatoid Arthritis (RA)24clinicaltrials.gov
May 21, 2025NCT06982534Clinical Study on the Treatment of Systemic Sclerosis With UTAA91 Injection.PersonGen BioTherapeutics (Suzhou) Co., Ltd.Early phase 1Not yet recruitingSystemic Sclerosis (SSc)24clinicaltrials.gov
May 14, 2025NCT06970951Early Clinical Study of UTAA91 Injection for the Treatment of Relapsed/Refractory Autoimmune DiseasesPersonGen BioTherapeutics (Suzhou) Co., Ltd.Early phase 1Not yet recruitingSystemic Lupus Erythematosus, Rheumatoid Arthritis, Dry Syndrome, Idiopathic Inflammatory Myopathies, Systemic Sclerosis15clinicaltrials.gov
March 12, 2025NCT06871644Clinical Study of CD7 CAR-T Cells for Relapsed/refractory Autoimmune DiseasesPersonGen BioTherapeutics (Suzhou) Co., Ltd.Not applicableNot yet recruitingSystemic Sclerosis - 2013 ACR/EULAR Classification Criteria18clinicaltrials.gov
May 16, 2024NCT06417398Preliminary Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune DiseasesPersonGen BioTherapeutics (Suzhou) Co., Ltd.Early phase 1UnknownSystemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies, Systemic Sclerosis, Sjogren's Syndrome, Rheumatoid...10clinicaltrials.gov
April 12, 2024NCT06361745Early Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune DiseasesPersonGen BioTherapeutics (Suzhou) Co., Ltd.Not applicableUnknownSystemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies, Systemic Sclerosis, IgG4 Related Disease, Primary...10clinicaltrials.gov
February 26, 2024NCT06279026UTAA17 Injection in the Treatment of Relapsed/Refractory Multiple MyelomaPersonGen BioTherapeutics (Suzhou) Co., Ltd.Not applicableRecruitingRelapsed/Refractory Multiple Myeloma15clinicaltrials.gov
October 23, 2023NCT06092047UTAA09 Injection in the Treatment of Relapsed/Refractory Hematolymphatic Malignancies.PersonGen BioTherapeutics (Suzhou) Co., Ltd.Early phase 1RecruitingCD19-positive Relapsed or Refractory B-cell Malignancies10clinicaltrials.gov
February 16, 2023NCT05731219UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid LeukemiaPersonGen BioTherapeutics (Suzhou) Co., Ltd.Phase 1UnknownRelapsed/Refractory Acute Myeloid Leukemia18clinicaltrials.gov
February 10, 2023NCT05722171Clinical Study of UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid LeukemiaPersonGen BioTherapeutics (Suzhou) Co., Ltd.Early phase 1UnknownRelapsed/Refractory Acute Myeloid Leukemia10clinicaltrials.gov
September 30, 2022NCT05562024TAA06 Injection in the Treatment of Patients With B7-H3-positive Relapsed/ Refractory NeuroblastomaPersonGen BioTherapeutics (Suzhou) Co., Ltd.Phase 1RecruitingB7-H3-positive Relapsed/ Refractory Neuroblastoma24clinicaltrials.gov
June 27, 2022NCT05432401TAA05 Injection in the Treatment of Adult Patients With FLT3-positive Relapsed/Refractory Acute Myeloid LeukemiaPersonGen BioTherapeutics (Suzhou) Co., Ltd.Early phase 1UnknownFLT3-positive Relapsed/Refractory Acute Myeloid Leukemia18clinicaltrials.gov
January 13, 2022NCT05190185A Clinical Trial of TAA06 Injection in Advanced Solid TumorsPersonGen BioTherapeutics (Suzhou) Co., Ltd.Phase 1UnknownMalignant Melanoma, Lung Cancer, or Colorectal Cancer18clinicaltrials.gov
December 28, 2021NCT05170568PA3-17 Injection Treatment of Adult Patients With CD7-positive Relapsed/Refractory Lymphoid Hematologic MalignanciesPersonGen BioTherapeutics (Suzhou) Co., Ltd.Phase 1UnknownCD7-positive Relapsed/Refractory Lymphoid Hematologic Malignancies22clinicaltrials.gov
August 24, 2021NCT05017883TAA05 Cell Injection in the Treatment of Recurrent / Refractory Acute Myeloid LeukemiaPersonGen BioTherapeutics (Suzhou) Co., Ltd.Not applicableUnknownCAR, Acute Myeloid Leukemia5clinicaltrials.gov
April 29, 2021NCT04864821Clinical Study of CD276 Targeted Autologous Chimeric Antigen Receptor T Cell Infusion in Patients With CD276 Positive Advanced Solid TumorPersonGen BioTherapeutics (Suzhou) Co., Ltd.Early phase 1UnknownOsteosarcoma, Neuroblastoma, Gastric Cancer, Lung Cancer24clinicaltrials.gov
March 8, 2021NCT04785833CD7 CAR-T in the Treatment of CD7 Positive Refractory Relapsed Acute LeukemiaPersonGen BioTherapeutics (Suzhou) Co., Ltd.Not applicableUnknownT-ALL20clinicaltrials.gov
January 11, 2021NCT04702841CAR - γ δ T Cells in the Treatment of Relapsed and Refractory CD7 Positive T Cell-derived Malignant TumorsPersonGen BioTherapeutics (Suzhou) Co., Ltd.Early phase 1UnknownCAR, Malignant Tumors8clinicaltrials.gov
January 7, 2021NCT04700319CAR-T CD19/CD20 for Patients With Advanced CD19/CD20+ B Cell Line Recurrent or Refractory Hematological MalignanciesPersonGen BioTherapeutics (Suzhou) Co., Ltd.Early phase 1UnknownCAR30clinicaltrials.gov
January 5, 2021NCT04692948TAA6 Cell Injection In The Treatment of Patients With Relapsed / Refractory Acute Myeloid LeukemiaPersonGen BioTherapeutics (Suzhou) Co., Ltd.Not applicableUnknownCAR, Acute Myeloid Leukemia5clinicaltrials.gov

By phase

PhaseTrials
Early phase 117
Phase 19
Phase 1/28
Phase 21
Not applicable8

By status

StatusTrials
Unknown30
Recruiting7
Not yet recruiting5
Completed1

Conditions

Condition groupTrials
Leukemia, Myeloid, Acute7
Precursor Cell Lymphoblastic Leukemia-Lymphoma6
Lymphoma, Mantle-Cell5
Lymphoma, Follicular5
Lymphoma, Large B-Cell, Diffuse4
Scleroderma, Systemic4
Lymphoma, Non-Hodgkin3
Arthritis, Rheumatoid3
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma3
Leukemia, Lymphocytic, Chronic, B-Cell3
Leukemia, Prolymphocytic, B-Cell3
Stomach Neoplasms3
Colorectal Neoplasms3
Lupus Erythematosus, Systemic3
Myositis3
Multiple Myeloma3
Neoplasms2
Carcinoma, Hepatocellular2
Carcinoma, Non-Small-Cell Lung2
Pancreatic Neoplasms2
Immunoblastic Lymphadenopathy2
Lymphoma, Extranodal NK-T-Cell2
Enteropathy-Associated T-Cell Lymphoma2
Lung Neoplasms2
Leukemia, B-Cell1

Where the register publishes

U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown. Free to quote with credit and a link. Copying in bulk needs a data licence. Spot a wrong value? Write to [email protected] with the link to this page.

$10 of credit on sign-up, no card.

Get this list free

Business lists in the United States

More public records